Last Update 12 Aug 26
Fair value Increased 14%DVA: Volume Execution And Margin Durability Will Shape Balanced Long Term Outlook
DaVita's analyst fair value estimate has been updated to $165 from $145 as analysts weigh a mix of higher and lower Street price targets, citing an improved long term outlook, evolving competitive positioning, and ongoing debates around volume growth and profitability.
Analyst Commentary
Recent research on DaVita highlights a wide spread in price targets and a mix of bullish and cautious views. Several firms lifted targets earlier in the year, while more recent updates point to some reassessment of upside as investors weigh volume trends, profitability, and execution on long term initiatives.
On the bullish side, some analysts raised price targets into the US$250 to US$270 range and kept positive ratings. These views point to DaVita's efforts around patient outcomes, advanced dialysis technologies, reduced missed treatments, and expanded home care services as important drivers for potential long term volume progress.
Other firms have fine tuned targets in smaller steps following DaVita's Q2 report, with revised figures in the US$218 to US$224 range. Commentary in these notes highlights that, even with sequential treatment growth, U.S. dialysis EBIT of US$538m came in US$50m below Street estimates and likely below investor expectations, which keeps the focus on margin consistency and earnings quality.
More recently, there have been both upward and downward target moves. One upgrade cited an improved long term outlook, DaVita's market position versus its largest competitor, and the potential from the MOTheR trial to support volume growth and share gains. At the same time, another firm cut its target to US$215 from US$250, signaling some reset of expectations on valuation or upside potential after earlier enthusiasm.
Across these reports, DaVita is framed as a company with visible long term initiatives but with near term scrutiny on how quickly volumes track toward internal goals and how consistently profitability lines up with Street expectations. That tension between growth opportunities and execution risk is feeding directly into the dispersion in price targets.
Bearish Takeaways
- Bearish analysts point to DaVita operating below its long term volume targets, which they see as a risk to growth assumptions and to how much investors are willing to pay for the stock.
- Even with sequential treatment growth, the reported U.S. dialysis EBIT of US$538m falling US$50m short of Street estimates raises questions about earnings durability and leaves less room for valuation upside if similar gaps recur.
- The reduction of at least one price target, to US$215 from US$250, signals that some prior optimism has moderated and that perceived upside versus current trading levels may be narrower than before.
- Encouraging commentary on volumes and new care modalities is not enough for more cautious analysts, who remain concerned that execution on growth initiatives may take longer than expected and that profitability could lag ambitious targets.
What’s in the News for DaVita
- DaVita features as a sponsor of the American Heart Association’s CKM Health Initiative, which targets cardiovascular kidney metabolic syndrome across more than 250,000 patients at 150 care sites in 15 regions. Source: American Heart Association CKM Health Initiative coverage.
- The CKM program focuses on integrated care models that link heart, kidney, diabetes, and obesity management, with DaVita involved in efforts to refine risk stratification, treatment pathways, and tools for clinicians. Source: American Heart Association CKM Health Initiative coverage.
- DaVita reported Q2 2026 revenue of US$3.55b and adjusted EPS of US$4.02 compared with analyst expectations of US$3.88 on US$3.49b in revenue. Management kept full year adjusted EPS guidance at a midpoint of US$14.65. Source: Q2 2026 earnings coverage.
- Despite the Q2 2026 earnings beat, DaVita’s stock price fell sharply, first by nearly 10% and later by 17%, as investors focused on margin sustainability, patient care costs, and rising debt levels that could limit financial flexibility. Source: Q2 2026 earnings coverage.
- DaVita has been added to several Russell value benchmarks including the Russell 1000 Value, Russell Midcap Value, Russell 3000 Value, Russell 3000E Value, and Russell 2500 Value indices, reflecting index provider decisions on membership criteria. Source: Russell index constituent updates.
Valuation Changes
- Fair Value has moved from $145.00 to $165.00, which is a moderate upward reset in the analyst fair value estimate for DaVita.
- Discount Rate has shifted from 8.06% to 8.40%, a small increase that implies a slightly higher required return in the valuation model.
- Revenue Growth has been adjusted from 2.53% to 2.03%, a modest step down in the long term top line growth assumption.
- Net Profit Margin has been refined from 7.46% to 7.51%, which is a very small upward change in expected profitability for DaVita.
- Future P/E has moved from 8.39x to 9.59x, indicating a higher valuation multiple assumption applied to DaVita’s forward earnings in the model.
Catalysts
About DaVita
DaVita provides kidney care services, including dialysis and value based care programs for patients with chronic and end stage kidney disease.
What are the underlying business or industry changes driving this perspective?
- DaVita is investing in its next generation clinical platform and AI tools that could eventually support lower patient care costs. However, the company is currently absorbing higher G&A and IT spending, which may limit any near term improvement in operating margins and earnings.
- Broad kidney disease prevalence and an aging population can support long term demand for dialysis. At the same time, recent headwinds such as severe flu, a hurricane and a cyber incident highlight how sensitive treatment volume and admissions are to external shocks, which can pressure revenue growth and scale benefits.
- DaVita Clinical Research is working on middle molecule clearance and other therapies that could support better outcomes and potentially longer time on therapy. However, the company expects these clinical processes to take roughly three years to show results, which delays any possible uplift to treatment volume, revenue and net margins.
- Value based care through Integrated Kidney Care may provide an additional income stream over time. Management also notes that program timing and payer data are hard to predict, which creates ongoing volatility in the recognition of IKC operating income and earnings.
- Ongoing work in revenue operations, including automation and AI to improve collections, can support revenue per treatment and operating income. Management also points out that payer mix and items like premium tax credits and Medicare Advantage enrollment remain uncertain, which can offset improvements in revenue per treatment and overall profitability.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on DaVita compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming DaVita's revenue will grow by 2.0% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 5.9% today to 7.5% in 3 years time.
- The bearish analysts expect earnings to reach $1.1 billion (and earnings per share of $21.08) by about August 2029, up from $822.5 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 9.7x on those 2029 earnings, down from 13.8x today. This future PE is lower than the current PE for the US Healthcare industry at 24.7x.
- The bearish analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.4%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Persistent pressure on treatment volumes, including the recent 1.5% year over year decline in U.S. treatments per day and elevated missed treatment rates, could indicate a weaker long term growth base for the core dialysis business. This would weigh on revenue and operating income.
- Ongoing shifts in payer mix, including uncertainty around Medicare Advantage enrollment and potential changes to enhanced premium tax credits on exchanges, could reduce the share of higher paying commercial patients. This would lower revenue per treatment and net margins.
- Large, multi year IT and AI investments that are currently lifting G&A and patient care costs may take longer than expected to translate into cost efficiencies. This would keep operating expenses elevated and limit growth in earnings and free cash flow.
- The Integrated Kidney Care business is still loss making, with an adjusted operating loss of US$21 million in the quarter and timing of government and payer settlements that remains unpredictable. Prolonged or wider losses here could offset profitability from the core dialysis segment and limit earnings growth.
- Secular clinical initiatives, such as work on middle molecule clearance and models to reduce hospitalizations, aim to improve mortality and time on therapy but are expected to take several years to show results. If these efforts do not materially improve long term patient retention, the company may not see the hoped for lift in treatment volume, revenue and net margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for DaVita is $165.0, which represents up to two standard deviations below the consensus price target of $218.43. This valuation is based on what can be assumed as the expectations of DaVita's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $270.0, and the most bearish reporting a price target of just $165.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $14.9 billion, earnings will come to $1.1 billion, and it would be trading on a PE ratio of 9.7x, assuming you use a discount rate of 8.4%.
- Given the current share price of $178.34, the analyst price target of $165.0 is 8.1% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on DaVita?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
